Daily Endocrinology Research Analysis
Analyzed 81 papers and selected 3 impactful papers.
Summary
Three papers stood out today: a mechanistic JCI study reveals the liver as a central regulator of ectopic calcification in Abcc6-deficient Pseudoxanthoma Elasticum, with bisphosphonates rescuing cardiac calcification in mice. A prospective Diabetes Care cohort benchmarks HbA1c, glycated albumin, and fructosamine against CGM in dialysis, detailing biomarker-specific biases. A 20-year Thyroid cohort shows chronic iodine excess and aging synergistically elevate TSH and mild subclinical hypothyroidism, with effects persisting despite iodine reduction.
Research Themes
- Hepatic-endocrine cross-talk in ectopic calcification
- Glycemic biomarker validity and bias in dialysis
- Iodine exposure, aging, and thyroid axis remodeling
Selected Articles
1. The liver regulates ectopic calcification in Abcc6-deficient models of Pseudoxanthoma Elasticum.
Using tissue-specific Abcc6 deletion, metabolomics, and functional assays, the authors show that hepatic (but not cardiac) Abcc6 loss is sufficient to drive post-injury dystrophic cardiac calcification, linked to defects in nucleotide metabolism and cellular respiration. Pharmacologic inhibition of hydroxyapatite growth with clodronate or etidronate rescued ectopic calcification in Abcc6-deficient states.
Impact: This work uncovers a liver-to-heart axis controlling dystrophic calcification in PXE and provides preclinical proof-of-concept that bisphosphonates can reverse the phenotype.
Clinical Implications: Suggests repurposing etidronate/clodronate to mitigate post-injury cardiac calcification in PXE and motivates liver-targeted strategies or circulating mediator monitoring for risk stratification.
Key Findings
- Liver-specific, but not heart-specific, Abcc6 deletion was sufficient to induce post-injury cardiac calcification.
- Metabolomics revealed deficiencies in nucleotide metabolism and cellular energetics with defects in cellular respiration.
- Ectopic calcification was primarily dystrophic; clodronate or etidronate treatment rescued cardiac calcification in Abcc6-deficient models.
Methodological Strengths
- Tissue-specific gene deletion enabling organ-level causality mapping
- Multi-omics integration with in vivo pharmacologic rescue
Limitations
- Preclinical murine models may not fully translate to human PXE pathophysiology
- Focused on post-injury cardiac calcification; effects on other PXE-affected tissues remain to be defined
Future Directions: Identify hepatic circulating mediators of mineralization control, evaluate class- and dose-effects of bisphosphonates, and initiate early-phase clinical trials in PXE.
Pseudoxanthoma Elasticum (PXE) is a rare disease caused by loss of function of the gene Abcc6 and characterized by ectopic calcification of multiple tissues, but the physiological reasons underlying ectopic calcification in PXE remain unclear. In a murine model of Abcc6 deficient PXE where animals develop robust cardiac calcification after heart injury, we show the critical importance of the liver in mediating ectopic cardiac calcification. Tissue-specific deletion of Abcc6 in the liver, but not in the heart was suffici
2. Accuracy, Variability, and Bias of Glycemic Biomarkers in Patients Treated With Maintenance Dialysis.
In 251 dialysis patients wearing 10-day CGM, HbA1c and glycated albumin correlated strongly with CGM mean glucose (r≈0.85), outperforming fructosamine (r≈0.70). However, all biomarkers showed clinically relevant biases: HbA1c by ESA dose, BMI, hemoglobin, and serum albumin; GA/fructosamine by dialysis modality, vintage, residual kidney function, and BMI.
Impact: Provides head-to-head, CGM-anchored evidence to guide biomarker selection and interpretation in dialysis—a population where HbA1c validity is debated.
Clinical Implications: Use HbA1c or GA to estimate average glycemia in dialysis, but adjust for identifiable biases (e.g., ESA dose, dialysis modality); consider CGM for calibration or when discordant.
Key Findings
- HbA1c and glycated albumin correlated strongly with CGM mean glucose (overall r=0.85 and r=0.87), higher than fructosamine (r=0.70).
- HbA1c exhibited bias from ESA dose, BMI, hemoglobin, and serum albumin.
- Glycated albumin and fructosamine were biased by dialysis modality/vintage, residual kidney function, and BMI.
Methodological Strengths
- Prospective community-based design with CGM as reference standard
- Concurrent evaluation of multiple biomarkers with covariate bias analysis
Limitations
- Short CGM duration (10 days) may not capture longer-term variability
- Single CGM device and dialysis population may limit generalizability
Future Directions: Develop correction algorithms incorporating ESA dose, dialysis modality, and BMI; test combined biomarker-CGM strategies in clinical workflows.
OBJECTIVE: Accurate assessment of glycemia in patients treated with maintenance dialysis is imperative and hampered by known biases of glycated hemoglobin (HbA1c) in kidney failure (KF). This study evaluated the accuracy, variability, and covariate bias of three glycemic biomarkers compared with glycemia measured by continuous glucose monitor (CGM) among people with and without diabetes treated with maintenance dialysis. RESEARCH DESIGN AND METHODS: In a prospective community-based cohort study, 251 participants treated with maintenance dialysis wore a Dexcom G6 Pro CGM for 10 days. We compared correlations of HbA1c, glycated albumin (GA), and fructosamine with CGM-derived mean glycemia and examined sources of bias. RESULTS: Participants (43% women; 63% with diabetes) had a median of 9.3 (interquartile range 8.5-9.4) valid days of CGM data. Mean (SD) HbA1c, GA, fructosamine, and mean CGM glucose were 6.2% (1.4%), 19.6% (6.3%), 351 (99) µmol/L, and 170 (63) mg/dL, respectively. HbA1c, GA, and fructosamine all strongly correlated with mean CGM blood glucose, with HbA1c and GA more correlated than fructosamine (overall, r = 0.85, r = 0.87, and r = 0.70, respectively; in diabetes, r = 0.84, r = 0.84, and r = 0.64, respectively). Compared with mean CGM glucose, HbA1c was significantly biased by erythropoiesis-stimulating agent dose, BMI, hemoglobin, and serum albumin; GA and fructosamine were biased by dialysis modality and vintage, residual kidney function, and BMI. CONCLUSIONS: HbA1c and GA were strongly correlated with mean CGM blood glucose, but all biomarkers had substantial bias by relevant clinical characteristics. HbA1c and GA may be useful assessments of average glycemia in patients treated with maintenance dialysis, if bias can be adequately addressed.
3. Chronic Iodine Excess and Aging Synergistically Impact Thyrotropin Elevation: A Prospective 20-Year Follow-Up Study in China.
In three North China communities followed for 20 years, higher baseline urinary iodine concentration predicted higher TSH. Among thyroid antibody–negative participants, all iodine-excess groups showed persistently higher median TSH, greater prevalence of mild subclinical hypothyroidism (TSH <10 mU/L), and reduced central thyroid hormone sensitivity, with aging amplifying TSH elevation despite iodine reduction.
Impact: Provides rare 20-year prospective evidence that chronic iodine excess induces a persistent upward TSH shift and mild SCH, with aging exerting a synergistic effect, informing screening thresholds and public health iodine policies.
Clinical Implications: In chronically iodine-excess settings, modest TSH elevations and mild SCH may persist even after iodine reduction; clinicians should consider iodine–age interactions when interpreting TSH and avoid overdiagnosis and overtreatment in older adults.
Key Findings
- Baseline TSH increased with initial urinary iodine concentration (UIC).
- After 20 years, iodine-excess groups had higher median TSH (e.g., EI-DI 2.19 mU/L vs SI-SI 1.81 mU/L) and higher mild SCH prevalence (e.g., EI-SI 12.3% vs SI-SI 5.3%) among thyroid antibody–negative individuals.
- Central thyroid hormone sensitivity was reduced in iodine-excess groups; TSH elevations persisted despite iodine intake reduction and were amplified by aging.
Methodological Strengths
- Long-term (20-year) prospective community-based follow-up
- Stratification by thyroid autoantibody status to minimize confounding by autoimmunity
Limitations
- Cohort size and attrition are not detailed in the abstract; potential selection bias cannot be excluded
- Generalizability beyond North China and specific iodine transitions requires caution
Future Directions: Define age-adjusted TSH reference ranges in iodine-excess populations and test risk-based thresholds for treating mild SCH considering iodine exposure history.
BACKGROUND: Chronic iodine excess is associated with increased serum thyrotropin (TSH) levels. We assessed the independent and interactive effects of iodine-excess transition outcomes and aging on TSH levels over 20-year follow-up. METHODS: The original prospective cohort study started in 1999 and focused on three communities in North China ( RESULTS: During 1999-2004, the baseline median TSH levels were positively associated with the initial UIC levels. After 20 years, for participants with negative thyroid antibodies, the three iodine-excess groups all exhibited elevated median TSH levels (SI-SI 1.81 mU/L vs. EI-DI 2.19 mU/L vs. EI-SI 2.08 mU/L vs. EI-EI 2.01 mU/L), an increased prevalence of mild subclinical hypothyroidism (SCH) with TSH <10.0 mU/L (SI-SI 5.3% vs. EI-DI 11.2% vs. EI-SI 12.3% vs. EI-EI 9.4%) and reduced central thyroid hormone sensitivity compared with the SI-SI group ( CONCLUSIONS: Elevated TSH levels induced by chronic iodine excess cannot be downregulated by reducing iodine intake. In nonautoimmune contexts, an interaction effect between iodine status and aging synergistically modulates the TSH rising degree. Iodine excess contributes to mild SCH and is correlated with high baseline TSH levels.